Arsenal Biosciences has raised $325 million in a Series C funding round, backed by major investors like Regeneron Ventures, Arch Venture Partners, and NVIDIA. The cell therapy biotech aims to advance its programs targeting kidney and prostate cancers, leveraging its innovative CRISPR-based technology. CEO Ken Drazan noted that despite the challenging investment climate, investor enthusiasm was fueled by confidence in the company's business plan for the next 18 months.

The funds will focus on ArsenalBio’s pipeline, particularly its kidney cancer candidate AB-2100, which is in a Phase 1/2 trial. The therapy uses the company's CRISPR-based CITE technology, designed to selectively target tumor cells while sparing healthy tissue. ArsenalBio's shift away from its previous ovarian cancer program allows the company to concentrate resources on solid tumors like kidney and prostate cancers, which the company sees as key areas of unmet need.

With a strong focus on innovation, ArsenalBio seeks to remain ahead of the competition by solving the challenges tied to cell therapies for solid tumors. Their proprietary toolkit, which integrates multiple functions into a single product, distinguishes ArsenalBio's approach. The new funding will also drive technological advancements, positioning the company to deliver comprehensive solutions to solid tumor treatment.

Click here to read the original news story.